Acute liver failure can be a fatal adverse effect of chronic myeloid leukemia treatment with imatinib. Is liver transplant a viable option for these patients?Journal of Medical Case Reports
Publication date: September 2018Source: Human Pathology: Case Reports, Volume 13Author(s): Emily Feldpausch, Shilpa Sambidi, Durga Cherukuri, Jagmohan SidhuAbstractThe myeloproliferative neoplasms (MPNs) are chronic myeloid cancers (clonal hematopoietic disorders) that are characterized by the overproduction of terminally differentiated (mature) blood cells, and that may evolve into acute myeloid leukemia (AML). The literature indicates that three known driver mutations currently exist in BCR/ABL1-negative MPNs: JAK2, MPL and CALR. A small percentage of BCR/ABL1-negative MPN cases lack mutations in all three of these genes…
Conclusion: Complex karyotype was most frequently associated with myelodysplastic syndromes and acute myeloid leukemia. Trisomy 21 and deletion 5q were the commonest cytogenetic abnormalities found. We also assessed complex karyotype in benign diseases and detected one patient of aplastic anemia with complex karyotype. This is the first study highlighting the presence of complex karyotypes in hematological disorders in our region.
PMID: 29971104 [PubMed]
ConclusionIn real life, ponatinib is a “niche-drug” reserved for a unique population of exceptionally young patients with CML with or without the T315I mutation. In this highly selected group, very different from the PACE cohort, ponatinib achieved high overall response rates.
Authors: Xie Y, Visconte V, Duan L, Rogers HJ
PMID: 29963524 [PubMed]
Authors: Shi M, Dong X, Huo L, Wei X, Wang F, Sun K
Hematological malignancies (HM) are a heterogeneous group of life-threatening hematological diseases. The heterogeneity and clonal evolution of HM subpopulations are the main obstacles for precise diagnoses, risk stratification, and even targeted therapies. Standard bulk-sample genomic examinations average total mutations from multiple subpopulations and conceal the clonal diversity that may play a significant role in HM progression. Therefore, the development of novel methods that detect intra-tumor heterogeneity is critical for the discovery of novel po…
Efficient lysis of B-chronic lymphocytic leukemia cells by the plant-derived sesquiterpene alcohol α-bisabolol, a dual proapoptotic and antiautophagic agent.
Oncotarget. 2018 May 25;9(40):25877-25890
Authors: Rigo A, Ferrarini I, Bonalumi A, Tecchio C, Montresor A, Laudanna C, Vinante F
The sesquiterpene α-bisabolol (α-BSB) is a cytotoxic agent against acute leukemia and chronic myeloid leukemia cells. Here the profile of α-BSB citotoxicity was evaluated ex vivo in primary mononuclear blood cells isolated from 45 untreated B-chronic lymphocytic leukemia (B-CLL) patients…
Authors: González ML, Joray MB, Laiolo J, Crespo MI, Palacios SM, Ruiz GM, Carpinella MC
Plants are a significant reservoir of cytotoxic agents, including compounds with the ability to interfere with multidrug-resistant (MDR) cells. With the aim of finding promising candidates for chemotherapy, 91 native and naturalized plants collected from the central region of Argentina were screened for their cytotoxic effect toward sensitive and MDR P-glycoprotein (P-gp) overexpressing human leukemia cells by means of MTT assays. The ethanol extracts obtained from Aldama tucumanensis, Ambrosia elatior, Bacchari…
Varicella zoster virus (VZV) is a member of Herpesviridae family. It can cause two distinct clinical entities: varicella (chickenpox) and herpes zoster (shingles).1,2Herpes Zoster(HZ) is painful, vesicular rash in a limited area on one side of body due to the reactivation of latent VZV in dorsal root ganglia.Involvement of three or more dermatomes is known as disseminated zoster and seen in immunocompromised individuals.It can occur at any age. The risk of herpes zoster increases with old age and in patients with reduced cell mediated immunity such as haematological malignancies, immunosuppressive therapies, HIV infection …
AbstractChromosome translocation t(16;21)(q24;q22)/RUNX1-RUNX1T3 is an infrequent but recurrent chromosomal abnormality identified in myeloid neoplasms, with only 25 cases have been reported to date. Here, we report eight cases (six women and two men) of myeloid neoplasms associated with t(16;21)(q24;q22): five with therapy-related myeloid neoplasms, two with relapsed acute myeloid leukemia (AML), and one with blast phase of chronic myeloid leukemia. Morphologic and immunophenotypic features include granulocytic dysplasia, blasts with prominent perinuclear hof, large orange-pink granules, long and slim Auer rods, and aberr…
Authors: Breccia M, Efficace F, Iurlo A, Luciano L, Abruzzese E, Gozzini A, Pregno P, Tiribelli M, Rosti G, Minotti G
INTRODUCTION: In spite of the proven efficacy of the tyrosine kinase inhibitor (TKI), imatinib, in chronic myeloid leukemia (CML), many patients develop intolerance and discontinue therapy in the long-term. Second-generation TKIs (dasatinib, nilotinib, bosutinib) and the third-generation TKI, ponatinib, have added opportunities but also complexity in the settings of CML treatment. Areas covered: Different definitions of intolerance have been used through several clinical trials, making the …